Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome

E-ISSN： 1600-0404|131|2|140-143

ISSN： 0001-6314

Source： ACTA NEUROLOGICA SCANDINAVICA (ELECTRONIC), Vol.131, Iss.2, 2015-02, pp. : 140-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

ANNALS OF NEUROLOGY, Vol. 77, Iss. 3, 2015-03 ,pp. : 425-435

John Wiley & Sons Inc

Access to resources Recommend Favorite

Persistent Headache in Patients With Multiple Sclerosis Starting Treatment With Fingolimod

HEADACHE, Vol. 55, Iss. 4, 2015-04 ,pp. : 578-579

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 10, 2015-10 ,pp. : 1131-1136

John Wiley & Sons Inc

Access to resources Recommend Favorite

Caregiver strain and factors associated with caregiver self-efficacy and quality of life in a community cohort with multiple sclerosis

By Khan Fary Pallant Julie Brand Caroline

Disability and Rehabilitation, Vol. 29, Iss. 16, 2007-01 ,pp. : 1241-1250

Informa Healthcare

Access to resources Recommend Favorite

Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis

By Bergvall Niklas Makin Charles Lahoz Raquel Agashivala Neetu Pradhan Ashish Capkun Gorana Petrilla Allison Karkare Swapna U. Balderston McGuiness Catherine Korn Jonathan R.

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1647-1656

Informa Healthcare

Access to resources Recommend Favorite